(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 September 2012 (07.09.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/117257 A8

(51) **International Patent Classification**:
A61K 9/00 (2006.01) ***A61P 35/00*** (2006.01)
A61K 31/56 (2006.01)

(21) **International Application Number**:
PCT/GB2012/050475

(22) **International Filing Date**:
2 March 2012 (02.03.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
13/040,143 3 March 2011 (03.03.2011) US

(71) **Applicant** *(for all designated States except US, UZ)*: **NAL PHARMACEUTICALS LTD.** [CN/CN]; Room 2109, Windsor House 311, Gloucester Road, Causeway Bay, Hong Kong (CN).

(71) **Applicant** *(for UZ only)*: **WALLACE, Sheila Jane** [GB/GB]; 90 Long Acre, London WC2E 9RA (GB).

(72) **Inventors**: **RYOO, Je Phil**; 6 Cromwell Court, Princeton, New Jersey 08540 (US). **CHU, Chun Kwong**; 1531 Herring Gull House, Shakok Estate, Shatin, Hong Kong (CN). **WANG, Zheng**; 408 Vanderveer Rd, Bridgewater, New Jersey 08807 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **CHOW, Diana Shu-Lian** [CA/US]; University of Houston, 4800 Calhoun Road, Houston, Texas 77004-2693 (US). **AKO, Roland A.** [CM/US]; University of Houston, 4800 Calhoun Road, Houston, Texas 77004-2693 (US).

(74) **Agent**: **WALLACE, Sheila Jane**; Marks & Clerk LLP, 90 Long Acre, London WC2E 9RA (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version**:
19 September 2013

(15) **Information about Correction**:
see Notice of 19 September 2013

WO 2012/117257 A8

(54) **Title**: DIETHYLSTILBESTROL DOSAGE FORM AND USE FOR THE TREATMENT OF PROSTATE OR BREAST CANCER

(57) **Abstract**: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.